Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
Virginia Brady MD
Virginia A. Brady MD Associate Editor
Geoffrey Connors MD, FACP
Geoffrey R. Connors MD, FACP Associate Editor
Shyoko Honiden MD, MSc
Shyoko Honiden MD, MSc Editor-in-Chief
See All Experts
Published in Respiratory Medicine and
1 other channel

Journal Scan / Research · March 13, 2023

Outcomes and Adverse Effects of Baricitinib vs Tocilizumab in the Management of Patients With Severe COVID-19

Critical Care Medicine

 

 Save  Recommend
 Share

Additional Info

Critical Care Medicine
Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19
Crit. Care Med. 2023 Mar 01;51(3)337-346, JH Peterson, NS Paranjape, N Grundlingh, JL Priestley

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated